A Single-Arm, Prospective, Multi-Center Study to Explore Maintained Efficacy With Ofatumumab Therapy in Patients With Relapsing Multiple Sclerosis Who Discontinue Intravenously Delivered Anti-Cd20 Monoclonal Antibody (Acd20 Mab) Therapy (Olikos)

1. Novartis Pharmaceuticals Corporation $19,360,727 133 payments

1. Caribbean Center For Clinical Research Organisation paid for research $2,782,661 3 payments
2. Uc Health Neuroscience Center Organisation paid for research $2,299,598 4 payments
3. University of South Florida Organisation paid for research $1,315,819 2 payments
4. Cleveland Clinic Hospital Teaching hospital · OH $1,264,631 2 payments
5. Alabama Neurology Associates Organisation paid for research $1,184,565 6 payments
6. Tallahassee Neurological Clinic Organisation paid for research $1,095,046 3 payments
7. Mdh Research LLC Organisation paid for research $1,075,262 2 payments
8. Central Texas Neurology Consultants Organisation paid for research $944,209 4 payments
9. Hope Neurology Pllc Organisation paid for research $847,016 2 payments
10. International Neurorehabilitation Institute Organisation paid for research $758,787 6 payments

Usually the institution or organisation running the study, not a person.